Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27401327
DOI
10.1016/j.jconrel.2016.07.012
PII: S0168-3659(16)30446-1
Knihovny.cz E-zdroje
- Klíčová slova
- Core-crosslinking, Drug release, Drug targeting, Nanomedicine, Polymeric micelles,
- MeSH
- akrylamidy chemie MeSH
- docetaxel MeSH
- doxorubicin chemie MeSH
- micely * MeSH
- molekulová hmotnost MeSH
- nosiče léků chemie MeSH
- polymery chemie MeSH
- reagencia zkříženě vázaná chemie MeSH
- taxoidy chemie MeSH
- uvolňování léčiv MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- akrylamidy MeSH
- docetaxel MeSH
- doxorubicin MeSH
- micely * MeSH
- N-(2-hydroxypropyl)methacrylamide MeSH Prohlížeč
- nosiče léků MeSH
- polymery MeSH
- reagencia zkříženě vázaná MeSH
- taxoidy MeSH
To optimally exploit the potential of (tumor-) targeted nanomedicines, platform technologies are needed in which physicochemical and pharmaceutical properties can be tailored according to specific medical needs and applications. We here systematically customized the properties of core-crosslinked polymeric micelles (CCPM). The micelles were based on mPEG-b-pHPMAmLacn (i.e. methoxy poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate]), similar to the block copolymer composition employed in CriPec® docetaxel, which is currently in phase I clinical trials. The CCPM platform was tailored with regard to size (30 to 100nm), nanocarrier degradation (1month to 1year) and drug release kinetics (10 to 90% in 1week). This was achieved by modulating the molecular weight of the block copolymer, the type and density of the crosslinking agent, and the hydrolytic sensitivity of the drug linkage, respectively. The high flexibility of CCPM facilitates the development of nanomedicinal products for specific therapeutic applications.
Citace poskytuje Crossref.org
